Overview

Reduced Intensity Total Body Irradiation + Thymoglobulin Followed by Allogeneic PBSCT

Status:
Completed
Trial end date:
2017-06-28
Target enrollment:
Participant gender:
Summary
One of two different doses of thymoglobulin will allow bone marrow engraftment with minimal Graft-versus-Host Disease and allow adequate immune response to allow the transplanted stem cells to replace the tumor cells.
Phase:
Phase 2
Details
Lead Sponsor:
Virginia Commonwealth University
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Antilymphocyte Serum
Mycophenolate mofetil
Mycophenolic Acid
Tacrolimus
Thymoglobulin